Thomas L Frandsen

List of Publications by Year
in descending order

83	3,032	172386 29	175177 52
papers	citations	h-index	g-index

88	88	88	3075
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Endothelial dysfunction and thromboembolism in children, adolescents, and young adults with acute lymphoblastic leukemia. Leukemia, 2022, 36, 361-369.	3.3	4
2	Can Machine Learning Models Predict Asparaginase-associated Pancreatitis in Childhood Acute Lymphoblastic Leukemia. Journal of Pediatric Hematology/Oncology, 2022, 44, e628-e636.	0.3	4
3	Asparaginase enzyme activity levels and toxicity in childhood acute lymphoblastic leukemia: a NOPHO ALL2008 study. Blood Advances, 2022, 6, 138-147.	2.5	11
4	Rehabilitation Including Structured Active Play for Preschoolers With Cancer (RePlay)â€"Study Protocol for a Randomized Controlled Trial. Frontiers in Pediatrics, 2022, 10, .	0.9	4
5	Relapse risk following truncation of pegylated asparaginase in childhood acute lymphoblastic leukemia. Blood, 2021, 137, 2373-2382.	0.6	42
6	TPMT polymorphisms and minimal residual disease after 6-mercaptopurine post-remission consolidation therapy of childhood acute lymphoblastic leukaemia. Pediatric Hematology and Oncology, 2021, 38, 227-238.	0.3	4
7	Citrulline as a biomarker of bacteraemia during induction treatment for childhood acute lymphoblastic leukaemia. Pediatric Blood and Cancer, 2021, 68, e28793.	0.8	13
8	National, clinical cohort study of late effects among survivors of acute lymphoblastic leukaemia: the ALL-STAR study protocol. BMJ Open, 2021, 11, e045543.	0.8	9
9	Increments in DNA-thioguanine level during thiopurine-enhanced maintenance therapy of acute lymphoblastic leukemia. Haematologica, 2021, 106, 2824-2833.	1.7	15
10	Maintenance therapy and risk of osteonecrosis in children and young adults with acute lymphoblastic leukemia: a NOPHO ALL2008 sub-study. Cancer Chemotherapy and Pharmacology, 2021, 88, 911-917.	1.1	5
11	Play interventions for paediatric patients in hospital: a scoping review. BMJ Open, 2021, 11, e051957.	0.8	26
12	Bovine Colostrum Against Chemotherapyâ€Induced Gastrointestinal Toxicity in Children With Acute Lymphoblastic Leukemia: A Randomized, Doubleâ€Blind, Placeboâ€Controlled Trial. Journal of Parenteral and Enteral Nutrition, 2020, 44, 337-347.	1.3	24
13	Flow cytometric detection of leukemic blasts in cerebrospinal fluid predicts risk of relapse in childhood acute lymphoblastic leukemia: a Nordic Society of Pediatric Hematology and Oncology study. Leukemia, 2020, 34, 336-346.	3.3	53
14	Asparaginase-Associated Pancreatitis in Acute Lymphoblastic Leukemia: Results From the NOPHO ALL2008 Treatment of Patients 1-45 Years of Age. Journal of Clinical Oncology, 2020, 38, 145-154.	0.8	49
15	Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia. The Cochrane Library, 2020, 10, CD013399.	1.5	6
16	Everyday life challenges among adolescent and young adult survivors of childhood acute lymphoblastic leukemia: An inâ€depth qualitative study. Psycho-Oncology, 2020, 29, 1630-1637.	1.0	22
17	Effect of Fish Oil Supplementation on Hyperlipidemia during Childhood Acute Lymphoblastic Leukemia Treatment â€“ A Pilot Study. Nutrition and Cancer, 2020, 73, 1-5.	0.9	6
18	Effects of a physical activity program from diagnosis on cardiorespiratory fitness in children with cancer: a national non-randomized controlled trial. BMC Medicine, 2020, 18, 175.	2.3	18

#	Article	IF	Citations
19	Gastrointestinal toxicity during induction treatment for childhood acute lymphoblastic leukemia: The impact of the gut microbiota. International Journal of Cancer, 2020, 147, 1953-1962.	2.3	32
20	Dyslipidemia at diagnosis of childhood acute lymphoblastic leukemia. PLoS ONE, 2020, 15, e0231209.	1.1	10
21	The Association between Asparaginase Enzyme Activity Levels and Toxicities in Childhood Acute Lymphoblastic Leukaemia in the NOPHO ALL2008 Protocol. Blood, 2020, 136, 30-30.	0.6	0
22	Hepatotoxicity during 6-thioguanine treatment in inflammatory bowel disease and childhood acute lymphoblastic leukaemia: A systematic review. PLoS ONE, 2019, 14, e0212157.	1.1	27
23	Intermittent Versus Continuous PEG-Asparaginase to Reduce Asparaginase-Associated Toxicities: A NOPHO ALL2008 Randomized Study. Journal of Clinical Oncology, 2019, 37, 1638-1646.	0.8	72
24	Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia. The Cochrane Library, 2019, , .	1.5	2
25	Insulinâ€dependent diabetes: A chronic complication to acute pancreatitis in childhood acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2019, 66, e27437.	0.8	10
26	Trypsin-encoding PRSS1-PRSS2 variations influence the risk of asparaginase-associated pancreatitis in children with acute lymphoblastic leukemia: a Ponte di Legno toxicity working group report. Haematologica, 2019, 104, 556-563.	1.7	36
27	Association between body mass index and pancreatitis in children with acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2018, 65, e27071.	0.8	8
28	Thromboembolism in acute lymphoblastic leukemia: results of NOPHO ALL2008 protocol treatment in patients aged 1 to 45 years. Blood, 2018, 131, 2475-2484.	0.6	83
29	Role of TPMT and ITPA variants in mercaptopurine disposition. Cancer Chemotherapy and Pharmacology, 2018, 81, 579-586.	1.1	18
30	Individualized 6â€mercaptopurine increments in consolidation treatment of childhood acute lymphoblastic leukemia: A NOPHO randomized controlled trial. European Journal of Haematology, 2018, 100, 53-60.	1.1	7
31	Treatmentâ€related mortality in relapsed childhood acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2018, 65, e26909.	0.8	24
32	Comparing osteonecrosis clinical phenotype, timing, and risk factors in children and young adults treated for acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2018, 65, e27300.	0.8	36
33	Testing physical function in children undergoing intense cancer treatmentâ€”a RESPECT feasibility study. Pediatric Blood and Cancer, 2018, 65, e27100.	0.8	17
34	Putative new childhood leukemia cancer predisposition syndrome caused by germline biâ€allelic missense mutations in DDX41. Genes Chromosomes and Cancer, 2018, 57, 670-674.	1.5	19
35	The cost of cure. Lancet Haematology,the, 2018, 5, e504-e505.	2.2	5
36	Hyperlipidemia is a risk factor for osteonecrosis in children and young adults with acute lymphoblastic leukemia. Haematologica, 2017, 102, e175-e178.	1.7	44

#	Article	IF	Citations
37	Hepatic sinusoidal obstruction syndrome during maintenance therapy of childhood acute lymphoblastic leukemia is associated with continuous asparaginase therapy and mercaptopurine metabolites. Pediatric Blood and Cancer, 2017, 64, e26519.	0.8	20
38	Evolution of modularity literature: a 25-year bibliometric analysis. International Journal of Operations and Production Management, 2017, 37, 703-747.	3.5	42
39	Successful Treatment of Rhino-Orbital-Cerebral Mucormycosis in a Child With Leukemia. Journal of Pediatric Hematology/Oncology, 2017, 39, e211-e215.	0.3	16
40	Early presentation of osteonecrosis in acute lymphoblastic leukemia: Two children from the Nordic and Baltic cohort. Pediatric Blood and Cancer, 2017, 64, e26624.	0.8	7
41	Asparaginase-associated pancreatitis in childhood acute lymphoblastic leukaemia: an observational Ponte di Legno Toxicity Working Group study. Lancet Oncology, The, 2017, 18, 1238-1248.	5.1	87
42	Prolonged firstâ€line PEGâ€asparaginase treatment in pediatric acute lymphoblastic leukemia in the NOPHO ALL2008 protocolâ€”Pharmacokinetics and antibody formation. Pediatric Blood and Cancer, 2017, 64, e26686.	0.8	31
43	Asparaginaseâ€associated pancreatitis is not predicted by hypertriglyceridemia or pancreatic enzyme levels in children with acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2017, 64, 32-38.	0.8	25
44	Asparaginase-associated pancreatitis: a study on phenotype and genotype in the NOPHO ALL2008 protocol. Leukemia, 2017, 31, 325-332.	3.3	55
45	Non-infectious chemotherapy-associated acute toxicities during childhood acute lymphoblastic leukemia therapy. F1000Research, 2017, 6, 444.	0.8	62
46	Toxicity profile and treatment delays in <scp>NOPHO ALL</scp>2008â€”comparing adults and children with Philadelphia chromosomeâ€negative acute lymphoblastic leukemia. European Journal of Haematology, 2016, 96, 160-169.	1.1	57
47	Measures of 6-mercaptopurine and methotrexate maintenance therapy intensity in childhood acute lymphoblastic leukemia. Cancer Chemotherapy and Pharmacology, 2016, 78, 983-994.	1.1	28
48	Leukemic blasts are present at low levels in spinal fluid in oneâ€third of childhood acute lymphoblastic leukemia cases. Pediatric Blood and Cancer, 2016, 63, 1935-1942.	0.8	37
49	Parentsâ€™ and Adolescentsâ€™ Preferences for Intensified or Reduced Treatment in Randomized Lymphoblastic Leukemia Trials. Pediatric Blood and Cancer, 2016, 63, 865-871.	0.8	7
50	Consensus definitions of 14 severe acute toxic effects for childhood lymphoblastic leukaemia treatment: a Delphi consensus. Lancet Oncology, The, 2016, 17, e231-e239.	5.1	194
51	Asparaginase-Associated Pancreatitis in Childhood Acute Lymphoblastic Leukemia: A Ponte Di Legno Toxicity Working Group Report on Clinical Presentation and Outcome. Blood, 2016, 128, 585-585.	0.6	1
52	Pharmacokinetics of 6-Thioguanine and 6-Mercaptopurine Combination Maintenance Therapy of Childhood ALL. Journal of Pediatric Hematology/Oncology, 2015, 37, e206-e209.	0.3	4
53	Myelotoxicity after high-dose methotrexate in childhood acute leukemia is influenced by 6-mercaptopurine dosing but not by intermediate thiopurine methyltransferase activity. Cancer Chemotherapy and Pharmacology, 2015, 75, 59-66.	1.1	19
54	Mercaptopurine metabolite levels are predictors of bone marrow toxicity following high-dose methotrexate therapy of childhood acute lymphoblastic leukaemia. Cancer Chemotherapy and Pharmacology, 2015, 75, 1089-1093.	1.1	16

#	Article	IF	Citations
55	The association between glucocorticoid therapy and BMI z-score changes in children with acute lymphoblastic leukemia. Supportive Care in Cancer, 2015, 23, 3573-3580.	1.0	12
56	Serial Ultrasound Monitoring for Early Recognition of Asparaginase Associated Pancreatitis in Children With Acute Lymphoblastic Leukemia. Pediatric Hematology and Oncology, 2015, 32, 474-481.	0.3	11
57	A novel chemosensitivity profiling platform for small acute lymphoblastic leukemia cell populations. Leukemia and Lymphoma, 2015, 56, 2208-2211.	0.6	0
58	Cerebral sinus venous thromboses in children with acute lymphoblastic leukaemia â€“ a multicentre study from the Nordic Society of Paediatric Haematology and Oncology. British Journal of Haematology, 2015, 168, 547-552.	1.2	65
59	Cerebrospinal fluid asparagine depletion during pegylated asparaginase therapy in children with acute lymphoblastic leukaemia. British Journal of Haematology, 2014, 166, 213-220.	1.2	27
60	Mercaptopurine/Methotrexate Maintenance Therapy of Childhood Acute Lymphoblastic Leukemia. Journal of Pediatric Hematology/Oncology, 2014, 36, 503-517.	0.3	181
61	Clinical features and early treatment response of central nervous system involvement in childhood acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2014, 61, 1416-1421.	0.8	26
62	Asparaginase-associated pancreatitis in children with acute lymphoblastic leukaemia in the NOPHO ALL2008 protocol. British Journal of Haematology, 2014, 165, 126-133.	1.2	71
63	Complying with the European Clinical Trials directive while surviving the administrative pressure â€“ An alternative approach to toxicity registration in a cancer trial. European Journal of Cancer, 2014, 50, 251-259.	1.3	72
64	A Retrospective Multicenter Study from the Nordic Society of Pediatric Hematology and Oncology (NOPHO) on Cerebral Sinus Venous Thromboses in Children with Acute Lymphoblastic Leukemia. Blood, 2014, 124, 584-584.	0.6	0
65	Intra-Tumoral Blast Heterogeneity and Implications for Minimal Residual Disease Detection in T-Cell Acute Lymphoblastic Leukemia. Blood, 2014, 124, 1076-1076.	0.6	0
66	Flow Cytometric Leukemic Blasts Detection in Cerebrospinal Fluid of Children with Acute Lymphoblastic Leukemia. Blood, 2014, 124, 3799-3799.	0.6	0
67	A Novel Chemosensitivity Profiling Platform for Small Acute Lymphoblastic Leukemia Cell Populations. Blood, 2014, 124, 3790-3790.	0.6	0
68	Venous Thromboembolism in Children with Acute Lymphoblastic Leukemia in Northern Europe. Blood, 2014, 124, 3652-3652.	0.6	0
69	Incorporation of 6â€Thioguanine Nucleotides into DNA During Maintenance Therapy of Childhood Acute Lymphoblastic Leukemiaâ€"The Influence of Thiopurine Methyltransferase Genotypes. Journal of Clinical Pharmacology, 2013, 53, 670-674.	1.0	31
70	Asparaginaseâ€associated pancreatitis in children. British Journal of Haematology, 2012, 159, 18-27.	1.2	101
71	Individualized toxicityâ€titrated 6â€mercaptopurine increments during highâ€dose methotrexate consolidation treatment of lower risk childhood acute lymphoblastic leukaemia. A Nordic Society of Paediatric Haematology and Oncology (NOPHO) pilot study. British Journal of Haematology, 2011, 155, 244-247.	1.2	10
72	Metabolism of tumour-derived urokinase receptor and receptor fragments in cancer patients and xenografted mice. Thrombosis and Haemostasis, 2004, 91, 403-411.	1.8	28

#	Article	IF	Citations
73	Metastasis of transgenic breast cancer in plasminogen activator inhibitor-1 gene-deficient mice. Oncogene, 2003, 22, 4389-4397.	2.6	72
74	A Precise and Efficient Stereological Method for Determining Murine Lung Metastasis Volumes. American Journal of Pathology, 2001, 158, 1997-2003.	1.9	44
75	Increased stromal expression of murine urokinase plasminogen activator in a human breast cancer xenograft model following treatment with the matrix metalloprotease inhibitor, batimastat. Breast Cancer Research and Treatment, 2001, 68, 225-237.	1.1	10
76	The Plasminogen Activator Inhibitor PAI-1 Controls in Vivo Tumor Vascularization by Interaction with Proteases, Not Vitronectin. Journal of Cell Biology, 2001, 152, 777-784.	2.3	307
77	Functional overlap between two classes of matrix-degrading proteases in wound healing. EMBO Journal, 1999, 18, 4645-4656.	3.5	225
78	The Urokinase Plasminogen Activation System in Breast Cancer. , 1999, , 325-345.		1
79	Plasminogen activator inhibitor type 1 (PAI-1), in cancer: A potential new target for antiinvasive and antimetastatic therapy. Drugs of the Future, 1998, 23, 873.	0.0	3
80	Effect of NCAMâ€transfection on growth and invasion of a human cancer cell line. Apmis, 1997, 105, 919-930.	0.9	14
81	1Î±,25-Dihydroxyvitamin D3 inhibits the invasive potential of human breast cancer cellsin vitro. Clinical and Experimental Metastasis, 1994, 12, 195-202.	1.7	75
82	Hormone resistance, invasiveness, and metastatic potential in breast cancer. Breast Cancer Research and Treatment, 1993, 24, 227-239.	1.1	58
83	Molecular and cellular analysis of basement membrane invasion by human breast cancer cells in Matrigel-basedin vitro assays. Breast Cancer Research and Treatment, 1993, 24, 241-255.	1.1	112